{"id":48736,"date":"2023-02-02T08:00:41","date_gmt":"2023-02-02T08:00:41","guid":{"rendered":"https:\/\/www.arisglobal.com\/?p=48736"},"modified":"2023-02-02T08:00:41","modified_gmt":"2023-02-02T08:00:41","slug":"arisglobal-launches-regulatory-information-management-solution-purpose-built-for-investigational-stage-companies","status":"publish","type":"post","link":"https:\/\/www.arisglobal.com\/media\/press-release\/arisglobal-launches-regulatory-information-management-solution-purpose-built-for-investigational-stage-companies\/","title":{"rendered":"ArisGlobal Launches Regulatory Information Management Solution Purpose-Built for Investigational-Stage Companies"},"content":{"rendered":"

The new solution, Investigational <\/span>Product<\/span> RIMS<\/a>, will <\/span>provide<\/span> key <\/span>foundational R<\/span>IMS <\/span>functionality<\/span> to <\/span>organizations poised for future growth.<\/span><\/span>\u00a0<\/span><\/em><\/p>\n

Miami, Florida, February 2, 2023<\/span><\/b>\u2013 ArisGlobal, the leading provider of life sciences software designed to automate core drug development functions with its end-to-end technology platform LifeSphere\u00ae, today announces the launch of Investigational Product RIMS<\/a>, an offering purpose built to meet the unique needs of life sciences and medical device companies as they progress through the investigational stages of drug development.<\/span>\u00a0<\/span><\/p>\n

A pre-validated, turnkey solution, Investigational Product RIMS<\/a> is ideal for emerging life sciences and medical device companies that have yet to receive marketing authorization for their products. To that end, cost and complexity are reduced by focusing on functionality that’s a high priority such as investigational submission and dossier planning, clinical trial authorization tracking and health authority commitment management.\u00a0<\/span>\u00a0<\/span><\/p>\n

“Companies working toward marketing authorization cannot afford for technology to be a burden and increase organizational complexity,” said Jim Hilferty, Associate Vice President of Regulatory Products at ArisGlobal. “Investigational Product RIMS<\/a> is designed to focus on the functionality needed to achieve the next clinical or regulatory milestone. As an added benefit, companies working in a compliant system built for life sciences can present a more polished, investor-ready package of product assets to support growth.”<\/span>\u00a0<\/span><\/p>\n

“As companies needs evolve, Investigational Product RIMS<\/a> makes it possible to step into more advanced functionality with little organizational disruption,” adds Hilferty. “You can repurpose accepted investigational submission content to apply for marketing authorization once regulators give the green light and turn on features like global registration tracking as a product portfolio matures.”<\/span>\u00a0<\/span><\/p>\n

Key Features of LifeSphere Investigational Product<\/span><\/b>\u00a0<\/span><\/p>\n